Clinical Trials Browser

Interventional × guadecitabine × Clear all

NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Phase 2 Terminated

9 enrolled 11 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

NCT02935361 2026-01-29

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Phase 1/2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03257761 2025-12-05

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02684162 2025-11-06

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Phase 2 Completed

55 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02998567 2025-08-17

HyPeR

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Phase 1 Active not recruiting

Lung Neoplasms

NCT03206047 2025-03-13

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

NCT01752933 2024-08-27

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Completed

52 enrolled 14 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02907359 2024-08-27

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Phase 3 Completed

417 enrolled 24 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03603964 2024-08-27

Guadecitabine Extension Study

Phase 2 Terminated

35 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02901899 2024-02-20

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

45 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03913455 2023-12-20

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Phase 2 Completed

24 enrolled 13 charts

Small Cell Lung Carcinoma

NCT03075826 2022-05-05

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Phase 2 Completed

22 enrolled 8 charts

Myeloproliferative Disorders

NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01966289 2021-03-30

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Phase 1 Completed

Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT02293993 2021-03-05

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Phase 1 Completed

21 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01896856 2020-10-06

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Phase 1/2 Completed

118 enrolled 16 charts

Neoplasm Metastasis

NCT02429466 2020-09-23

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Phase 1 Completed

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT02892318 2020-03-13

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04250246 2020-01-31

NIBIT-ML1

Phase 2 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

Small Cell Lung Carcinoma

NCT03454984 2018-11-15

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02608437 2015-11-18

NIBIT-M4

Phase 1 Unknown

Melanoma